TY - JOUR T1 - Modelling the adjustment of COVID-19 response and exit from dynamic zero-COVID in China JF - medRxiv DO - 10.1101/2022.12.14.22283460 SP - 2022.12.14.22283460 AU - Kathy Leung AU - Gabriel M. Leung AU - Joseph T. Wu Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/12/14/2022.12.14.22283460.abstract N2 - Background Since the initial Wuhan outbreak, China has been containing COVID-19 outbreaks through its “dynamic zero-COVID” policy. Striking a balance between sustainability and cost-benefit, China has recently begun to adjust its COVID-19 response strategies, e.g. by announcing the “20 measures” on 11 November and further the “10 measures” on 7 December 2022. Strategies for safely exiting from dynamic zero-COVID (i.e. without catastrophically overburdening health systems and/or incurring unacceptably excessive morbidity and mortality) are urgently needed.Methods We use simulations to assess the respective and combined effectiveness of fourth-dose heterologous boosting, large-scale antiviral treatment and public health and social measures (PHSMs) that might allow China to further adjust COVID-19 response and exit from zero-COVID safely after 7 December 2022. We also assess whether local health systems can cope with the surge of COVID-19 cases posed by reopening, given that chunyun, a 40-day period with extremely high mobility across China associated with Spring Festival, will begin on 7 January 2023.Findings Reopening against Omicron transmission should be supported by the following interventions: 1) fourth-dose heterologous boosting 30-60 days before reopening by vaccinating 4-8% of the population per week with ≥85% uptake across all ages; 2) timely antiviral treatment with ≥60% coverage; 3) moderate PHSMs to reduce transmissibility by 47-69%. With fourth-dose vaccination coverage of 85% and antiviral coverage of 60%, the cumulative mortality burden would be reduced by 26-35% to 448-503 per million, compared with reopening without any of these interventions. Simultaneously reopening all provinces under current PHSMs would still lead to hospitalisation demand that are 1.5-2.5 times of surge hospital capacity (2.2 per 10,000 population per day).Interpretation Although the surge of disease burden posed by reopening in December 2022 – January 2023 would likely overload many local health systems across the country, the combined effect of vaccination, antiviral treatment and PHSMs could substantially reduce COVID-19 morbidity and mortality as China transits from dynamic-zero to normality. Planning for such a nationwide, coordinated reopening should be an urgent priority as part of the global exit from the acute phase of the COVID-19 pandemic.Funding COVID-19 Vaccines Evaluation Program, Chinese Center for Disease Control and Prevention; Health and Medical Research Fund, Health Bureau, The Government of the Hong Kong SAR; General Research Fund, Research Grants Council, Hong KongEvidence before this study We searched PubMed and preprint archives for articles published up to 7 December 2021, that contained information about exit strategies of zero-COVID or reopening in China after the emergence of Omicron using the terms “China”, “Omicron”, “B.1.1.529”, “COVID-19”, “SARS-CoV-2”, “vaccin*”, “vaccine”, “antiviral”, “control measures”, “non-pharmaceutical intervention”, “public health and social measure”, “zero-COVID”, “exit strategy” and “reopen*”. We only found one study by Wang et al (doi: 10.1101/2022.05.07.22274792) but they assessed the feasibility of sustaining SARS-CoV-2 containment with zero-COVID strategy in China. To our knowledge, there is no discussion of exit strategies of the zero-COVID strategy or assessment of feasibility of reopening in China.Added value of this study Reopening against Omicron transmission should be supported by the following interventions: 1) fourth-dose heterologous boosting 30-60 days before reopening by vaccinating 4-8% of the population per week with ≥85% uptake across all ages; 2) timely antiviral treatment with ≥60% coverage; 3) moderate PHSMs to reduce transmissibility by 47-69%. With fourth-dose vaccination coverage of 85% and antiviral coverage of 60%, the cumulative mortality burden would be reduced by 26-35% to 448-503 per million, compared with reopening without any of these interventions. Simultaneously reopening all provinces under current PHSMs would still lead to hospitalisation demand that are 1.5-2.5 times of surge hospital capacity (2.2 per 10,000 population per day).Implications of all the available evidence Although the surge of disease burden posed by reopening in December 2022 – January 2023 would likely overload many local health systems across the country, the combined effect of vaccination, antiviral treatment and PHSMs could substantially reduce COVID-19 morbidity and mortality as China transits from dynamic-zero to normality. Planning for such a nationwide, coordinated reopening should be an urgent priority as part of the global exit from the acute phase of the COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the COVID-19 Vaccines Evaluation Program (COVEP) of The Chinese Center for Disease Control and Prevention (grant no.: 2202-HK-25), Health and Medical Research Fund (grant no.: 21200122, CID-HKU2 and COVID19F05), Health and Medical Research Fund Research Fellowship Scheme (grant no.: 06200097), General Research Fund (grant no.: 17110020), and the AIR@InnoHK administered by Innovation and Technology Commission of The Government of the Hong Kong Special Administrative Region. KL was supported by the Enhanced New Staff Start-up Research Grant from LKS Faculty of Medicine, The University of Hong Kong. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We collated all data from publicly available data sources. All data included in the analyses are available in the main text or the supplementary materials.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe collated all data from publicly available data sources. All data included in the analyses are available in the main text or the supplementary materials. ER -